Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 17/20 | 0.75 |
| ▸ | GABRB3 | P28472 | 17/20 | 0.75 |
| ▸ | GABRA5 | P31644 | 17/20 | 0.75 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.68 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.68 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.68 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.68 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.68 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3571844 | 0.89 | GABRG2 (0.75) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL2825410 | 0.88 | GABRG2 (0.69) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL2824446 | 0.88 | GABRG2 (0.69) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL3571594 | 0.87 | GABRG2 (0.68) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL3571855 | 0.86 | GABRG2 (0.66) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL3919167 | 0.85 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL3574483 | 0.85 | GABRG2 (0.65) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL8801828 | 0.82 | GABRG2 (0.70) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL6866732 | 0.82 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| Ro-151310 SCHEMBL5748925 | 0.81 | GABRA1 (1.00) | GABRG2GABRB3GABRA5GABRA1GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1805184-B1 | IMIDAZO-BENZODIAZEPINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2013-01-09 | — | — | EP | disclosed |
| US-8293730-B2 | Substituted imidazo[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20100075954-A1 | SUBSTITUTED IMIDAZO[1,5-A][1,2,4]TRIAZOLO[1,5-D][1,4]BENZODIAZEPINE DERIVATIVES | KNUST HENNER | 2010-03-25 | — | — | US | disclosed |
| US-7671048-B2 | Substituted imidazo [1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7514426-B2 | Substituted imidazol[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-7507728-B2 | Halogen substituted imidazol[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-03-24 | — | — | US | disclosed |
| EP-1809297-B1 | IMIDAZO[1,5A]TRIAZOLO[1,5D]BENZODIAZEPINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE DISORDERS | HOFFMANN LA ROCHE (CH) | 2008-07-30 | — | — | EP | disclosed |
| EP-1807432-A1 | HALOGEN SUBSTITUTED BENZODIAZEPINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-07-18 | — | — | EP | disclosed |
| EP-1805184-A1 | IMIDAZO-BENZODIAZEPINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006045429-A1 | HALOGEN SUBSTITUTED BENZODIAZEPINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-04 | — | — | WO | disclosed |
| WO-2006045430-A1 | IMIDAZO-BENZODIAZEPINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-04 | — | — | WO | disclosed |
| US-20060084801-A1 | Halogen substituted imidazol[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-20 | — | — | US | disclosed |
| US-20060084642-A1 | gamma-aminobutyric acid GABA receptors inverse agonists ; Alzheimer's disease, cognition enhancers; 10-methyl-9H-imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine | HOFFMANN-LA ROCHE INC. | 2006-04-20 | — | — | US | disclosed |
| US-20060079507-A1 | Substituted imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives | HOFFMANN-LA ROCHE INC. | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084642-A1 | gamma-aminobutyric acid GABA receptors inverse agonists ; Alzheimer's disease, cognition enhancers; 10-methyl-9H-imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine | GABRA3, GABRA1, GABRA4 | GABRG2 14/4885GABRB3 4/4885GABRA5 6/4885 |
| US-20060079507-A1 | Substituted imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives | GABRA3, GABRA1, OXER1 | GABRG2 73/4885GABRB3 10/4885GABRA5 16/4885 |
| US-20060084801-A1 | Halogen substituted imidazol[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | GABRA1, GABRA4, GABRA5 | GABRG2 24/4885GABRB3 10/4885GABRA5 3/4885 |
| US-20100075954-A1 | SUBSTITUTED IMIDAZO[1,5-A][1,2,4]TRIAZOLO[1,5-D][1,4]BENZODIAZEPINE DERIVATIVES | GABRA1, GABRA5, ADRA1A | GABRG2 43/4885GABRB3 19/4885GABRA5 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.